Global Proteomics Market Assessment, By Products and Services [Instruments, Reagents and Consumables, Services], By Technology [Spectrometry, Electrophoresis, Chromatography, Microarray Instruments, X-Ray Crystallography, Next-generation Sequencing, Protein Fractionation Systems, Surface Plasma Resonance Systems, Others], By Application [Drug Discovery and Development, Disease Diagnosis, Others], By End-user [Academic and Research Institutes, Clinical Laboratories and Hospitals, Pharmaceutical and Biotechnology Companies, Others], By Region, Opportunities and Forecast, 2018-2032F

Global proteomics market is projected to witness a CAGR of 12.50% during the forecast period 2025-2032, growing from USD 29.70 billion in 2024 to USD 76.21 billion in 2032. The market’s growth is supported by the rising requirement for personalized medicines, increasing demand for advanced and rapid diagnostic solutions, and growing emphasis on research and development activities. Continuous improvements in protein analysis technologies, such as mass spectrometry and bioinformatics, are enhancing the capabilities of proteomics, increasing its application across various fields such as clinical diagnostics and drug discovery.

Growing efforts of various companies to improve proteomics platforms are also supporting the market’s expansion. In November 2024, Quantum-Si Incorporated, specializing in protein sequencing technology, and NVIDIA Corporation announced a partnership to develop the former’s proteomics platform, Proteus, and improve their core technologies with the help of the latter’s accelerated computing capabilities and artificial intelligence. The collaboration also aims to address the rising demand for Quantum-Si's protein sequencing and detection technology and bolster data processing speed. Rising investments and funding are allowing the development of proteomics technologies that ensure early disease detection. In February 2024, Alamar Biosciences, Inc., one of the leading precision proteomics companies, announced the first closing of USD 100 million in Series C financing. Such fundings are expected to accelerate the development of non-invasive tests for diseases with significant unmet requirements and bolster the discovery of biomarkers.

Furthermore, government initiatives are also playing a crucial role in the development of innovative strategies that play a crucial role in maintaining human health. In September 2023, the National Institutes of Health (NIH) awarded USD 50.3 million for multi-omics research on human diseases and health. Such fundings aim to advance multi-omics research, which integrates various biological data types, including proteomics, to improve the understanding of diseases and support the development of scalable research strategies.

Rising Prevalence of Infectious and Chronic Diseases Boosts Market Demand

The growing threat of various infectious and chronic diseases is boosting the global proteomics market size. As per the estimates of the National Cancer Institute (NCI), approximately 2 million cases of cancer are expected to be diagnosed in the United States in 2024. This increase is augmenting the requirement for proteomics as the field has emerged as a crucial tool for exploring the different biological changes observed in cancer. Cancer is characterized by abnormal growth of the cells, where the normal cell cycle is disrupted because of genetic factors. With the help of proteomics technology, researchers have identified important information, including signaling pathways and protein targets linked with cancer cell growth.

The rising burden of infectious diseases is also bolstering the market’s demand as, over the past few years, proteomics and mass spectrometry-based technologies have been increasingly deployed for providing insights into the biological factors behind infectious diseases and characterizing the molecular details of pathogen-host relationships.

Increasing Investments Towards Proteomics Technologies Support Market Expansion

The rising investments towards advancing and accelerating the development of novel technologies in spatial proteomics and protein purification are positively influencing the expansion of the global proteomics market. In December 2024, SYNCELL, Inc., one of the leading companies in spatial proteomics analysis and next-generation subcellular protein purification, announced the closing of a USD 15 million Series A funding round to accelerate and expand the commercialization of their Microscoop platform. The pioneering platform has the ability to discover novel protein components accurately and allows unbiased, high-precision, and spatial proteomic discovery in cells and subcellular tissues.

Other factors propelling the investments in the proteomics industry include increasing emphasis on therapeutic proteins and monoclonal antibodies and rising applications of proteomics in translational research and clinical trials to accelerate the development of novel therapeutic solutions. Additionally, the growing focus of research and academic institutions in the healthcare sector to enhance patient outcomes and ensure the development of novel treatment and diagnostic options is further driving innovations in the proteomics sector.

Drug Discovery Segment Accounts for Significant Share of the Market

The rising investments in drug discovery can be attributed to the growing burden of chronic diseases and increasing investments by the pharmaceutical sector in research and development activities to address the unmet medical requirements of the patient population. Rapid innovations in various sectors, including artificial intelligence, genomics, and proteomics, are revolutionizing drug discovery, enabling precise targeting of disease mechanisms and resulting in the development of more effective and personalized therapies. Increasing collaborations between pharmaceutical and biotech companies and academic institutions foster innovation, further accelerating the drug discovery processes and bolstering the global proteomics market demand.

Additionally, various leading players in proteomics solutions are significantly investing in expanding their facilities to support the rising requirements for proteomics in the drug discovery and development sectors. In October 2024, Evosep Biosystems announced the relocation of its headquarters in Odense, Denmark. The new facility will reinforce the company’s commitment to improving diagnostic and drug discovery and development processes by serving as a hub for continued innovation. The relocation is also expected to help Evosep to expand its reach in the pharmaceutical industry and align its efforts for delivering end-to-end solutions that address the evolving requirements of the biotech and pharmaceutical companies.

North America Holds Major Market Share

The rapid growth of the North American proteomics market can be attributed to the rapid expansion of the biotechnology and healthcare industries in the region, the strong presence of leading market players, increasing investments towards the development of precision medicine, and the easy availability of novel therapeutic solutions. The demand for the next generation of medicines is driven by the rising cases of age-related disorders, neurological issues, immunological diseases, infections, and cancer, among others. Furthermore, the rising cases of hereditary disorders in countries such as Canada and the United States are also bolstering the region's proteomics requirement.

Additionally, the presence of leading research institutions and their rising efforts to support advancements in proteomics research also provide lucrative growth opportunities for the market. In October 2024, the University of Arkansas for Medical Sciences (UAMS) and Thermo Fisher Scientific Inc. announced the Thermo Fisher Scientific Center of Excellence for Proteomics launch at UAMS. The first industry-academic partnership of its kind in the United States, the development of the center is expected to allow clinicians and researchers to identify unique mechanisms that are responsible for driving various human diseases, novel drug targets, and new disease biomarkers.

Download Free Sample Report

Future Market Scenario (2025-2032F)

As per the global proteomics market analysis, the market is expected to observe significant growth in the coming years owing to the rapid expansion of the healthcare sector and the rising requirement for novel drug launches due to the exponential growth of the population and the rising threat of various chronic diseases. According to estimates from the United Nations, the global population is expected to reach 9.7 billion by 2050.

Medical research is expected to significantly benefit from the rising utilization of proteomics, allowing the identification of new therapeutic agents and targets and supporting the development of advanced prognostic and diagnostic tests. Additionally, the emerging technologies of protein arrays and chips are expected to enhance the throughput of analytical tests in the coming years.

The convergence of advanced technologies and rising proteomics applications in biotechnology, healthcare, and pharmaceutical industries are also expected to provide lucrative growth opportunities to the market in the coming years. Moreover, strategic collaborations between pharmaceutical companies, academic institutions, and proteomic service providers will play a crucial role in addressing the unmet requirements of the clinical sector.

Report Scope

“Proteomics Market Assessment, Opportunities and Forecast, 2018-2032F”, is a comprehensive report by Markets and Data, providing in-depth analysis and qualitative and quantitative assessment of the current state of global proteomics market, industry dynamics, and challenges. The report includes market size, segmental shares, growth trends, opportunities, and forecast between 2025 and 2032. Additionally, the report profiles the leading players in the industry, mentioning their respective market share, business models, competitive intelligence, etc.

Report Attribute	Details
Base Year of the Analysis	2024
Historical Period	2018-2023
Forecast Period	2025-2032
Projected Growth Rate	CAGR of 12.50% between 2025 and 2032
Revenue Forecast in 2032	USD 76.21 billion
Segments Covered	Products and Services, Technology, Application, End-user
Regions Covered	North America, Europe, South America, Asia-Pacific, Middle East and Africa
Key Companies Profile	Thermo Fisher Scientific Inc., Danaher Corporation, Agilent Technologies, Inc., Illumina, Inc., Bio-Rad Laboratories, Inc., Merck KGaA, Waters Corporation, Bruker Corporation, PerkinElmer AES, Shimadzu Corporation
Customization Scope	15% free report customization with purchase
Pricing and Purchase Options	Avail the customized purchase options to fulfill your precise research needs
Delivery Format	PDF and Excel through email (subject to the license purchased)

In the report, global proteomics market has been segmented into the following categories: 

• By Products and Services
  • Instruments
  • Reagents and Consumables
  • Services
• By Technology
  • Spectrometry
  • Electrophoresis
  • Chromatography
  • Microarray Instruments
  • X-Ray Crystallography
  • Next-generation Sequencing
  • Protein Fractionation Systems
  • Surface Plasma Resonance (SPR) Systems
  • Others
• By Application
  • Drug Discovery and Development
  • Disease Diagnosis
  • Others
• By End-user
  • Academic and Research Institutes
  • Clinical Laboratories and Hospitals
  • Pharmaceutical and Biotechnology Companies
  • Others
• By Region
  • North America
  • Europe
  • Asia-Pacific
  • South America
  • Middle East and Africa

Key Players Landscape and Outlook

The key players in the market are actively engaging in mergers, acquisitions, and collaborations to expand their product portfolio and their presence in the proteomics market. In July 2024, Thermo Fisher Scientific Inc. announced the completion of the acquisition of Olink Holding AB, one of the leading providers of next-generation proteomics solutions. The USD 3.1 billion deal is anticipated to aid Thermo Fisher in advancing precision medicine and enhancing the understanding of human biology. Olink’s proteomics solutions are complementary to Thermo Fisher’s life sciences and mass spectrometry offerings and are expected to allow the latter to accelerate scientific breakthroughs and drug discovery.

The leading market players are also investing in expanding their production facilities to boost the production of different products and technologies. In June 2024, Bruker Corporation opened its production facility in Bremen, Germany. This event is a significant milestone in the company’s commitment to ensure collaboration, innovation, and sustainability in the field of mass spectrometry. The facility is also expected to aid the company in meeting the growing demands for its products that are actively being adopted in various fields, including clinical proteomics, environmental analysis, and microbiology.

Key Players Operating in Global Proteomics Market are:

• Thermo Fisher Scientific Inc.
• Danaher Corporation
• Agilent Technologies, Inc.
• Illumina, Inc.
• Bio-Rad Laboratories, Inc.
• Merck KGaA
• Waters Corporation
• Bruker Corporation
• PerkinElmer AES
• Shimadzu Corporation

Markets and Data’s reports answer the following questions:

• What is the current and future market size of the product/service in question globally or specific to different countries?
• How are the markets divided into different product/service segments and the market size and growth of each segment?
• What is the market potential of different product segments and their investment case?
• How are the markets predicted to develop in the future and what factors will drive or inhibit growth?
• What is the business environment and regulatory landscape specific to the product/service?

If you can't find what you're searching for or have any custom requirements for global proteomics market, you may approach our team at info@marketsandata.com.